Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director George Poste sold 33,725 shares of Exelixis stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $26.89, for a total value of $906,865.25. Following the sale, the director now directly owns 199,020 shares of the company’s stock, valued at approximately $5,351,647.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
George Poste also recently made the following trade(s):
- On Tuesday, May 21st, George Poste sold 11,686 shares of Exelixis stock. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56.
Exelixis Stock Performance
NASDAQ:EXEL opened at $26.30 on Thursday. The stock has a market capitalization of $7.97 billion, a PE ratio of 41.09, a P/E/G ratio of 0.60 and a beta of 0.54. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $27.53. The company has a fifty day moving average of $22.98 and a two-hundred day moving average of $22.41.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
EXEL has been the subject of several recent research reports. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. TD Cowen boosted their price objective on Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. JMP Securities boosted their price target on Exelixis from $27.00 to $29.00 and gave the company a “market outperform” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.43.
Check Out Our Latest Analysis on Exelixis
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- How to Find Undervalued Stocks
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Stocks That Could Beat the September Blues
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.